Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Neuropsychopharmacol. 2014 Feb;24(2):223-31. doi: 10.1016/j.euroneuro.2013.11.012. Epub 2013 Dec 1.

Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.

Author information

1
Parc Sanitari Sant Joan de Déu, Spain; Fundació Sant Joan de Déu, Spain; Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Departament de Psiquiatriai Medicina Legal, Universitat Autònoma d eBarcelona,Spain. Electronic address: mehuerta@pssjd.org.
2
Parc Sanitari Sant Joan de Déu, Spain; Fundació Sant Joan de Déu, Spain; Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Spain.
3
Parc Sanitari Sant Joan de Déu, Spain; Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Spain.
4
Corporació Sanitària Parc Taulí, Spain.
5
Parc Sanitari Sant Joan de Déu, Spain.
6
Parc Sanitari Sant Joan de Déu, Spain; redIAPP "Financiado por el Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Red RD06/0018/0017", Spain.

Erratum in

  • Eur Neuropsychopharmacol. 2015 Jun;25(6):966.

Abstract

Studies of estrogen therapy in postmenopausal women provide evidence of an effect of sex hormones on cognitive function. Estrogen has demonstrated some utility in the prevention of normal, age-related decline in cognitive functions, especially in memory. The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized. Raloxifene, a selective estrogen receptor modulator (SERM), appears to act similarly to conjugated estrogens on dopamine and serotonin brain systems, and may be a better option since it lacks the possible negative effects of estrogen on breast and uterine tissue. We assessed the utility of raloxifene as an adjuvant treatment for cognitive symptoms in postmenopausal women with schizophrenia in a 12-week, double-blind, randomized, placebo-controlled study. Patients were recruited from both the inpatient and outpatient departments. Thirty-three postmenopausal women with schizophrenia (DSM-IV) were randomized to receive either adjuvant raloxifene (16 women) or adjuvant placebo (17 women) for three months. The main outcome measures were: Memory, attention and executive functions. Assessment was conducted at baseline and week 12. The total sample is homogenous with respect to: age, years of schooling, illness duration, baseline symptomatology and pharmacological treatment. The addition of raloxifene (60 mg) to regular antipsychotic treatment showed: we found significant differences in some aspects of memory and executive function in patients treated with raloxifene. This improvement does not correlate with clinical improvement. The use of raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia seems to be useful in improving cognitive symptoms.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01041092.

KEYWORDS:

Cognitive function; Postmenopausal women; Raloxifene; Schizophrenia

PMID:
24342775
DOI:
10.1016/j.euroneuro.2013.11.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center